agil remain wide moat life
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
water tool help client perform scientif research provid
analyt instrument servic suppli compani
special liquid chromatographi mass spectrometri
sale use primarili
pharmaceut firm analyz molecul structur
drug discoveri develop product process
tool also use food environment qualiti test
well industri applic addit help
scientist examin physic properti variou materi
thermal analysi tool
includ preinstal softwar sale provid
variou servic throughout use life system
sell relat consum chromatographi column
sampl prepar kit tool half
sale consid recur even instrument sale
rel sticki especi highli regul pharmaceut
end market repres half sale
appreci water concentr highli regul space
signific mani life science/diagnost
peer given healthi growth profil signific switch
cost associ pharmaceut field concentr
help grow midsingl digit continu
howev growth under-perform expect
recent end-market challeng includ declin
china sale earli competit pressur
like agil step lc-m product
offer although manag may mistim product
refresh cycl bit compani recent launch lc-m tool
bioaccord cater specif need biologic-focus
custom help compani regain foot also
infrastructur gener pharmaceut price creat
near-term challeng exposur china long-term posit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
offer liquid chromatographi mass spectrometri thermal
analysi tool primarili biopharmaceut
custom analyt instrument provid essenti inform
variou product molecular structur physic properti
help client enhanc health well-b end user
instruments/informat servic consum account
approxim sale respect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
agil remain wide moat
take fresh look top-tier analyt instrument
provid agil maintain wide
moat rate make uniqu life scienc
diagnost industri comparison cover
compani industri earn narrow moat rate
think agil heavi concentr
sticki end market -- biopharmaceut chemic
energi --
reproduc regulatori factor associ
tool contribut wider moat peer
firm enjoy exemplari stewardship rate well
specif disciplin acquisit record recent
year contribut return invest capit
doubl capit cost set apart industri
also help avoid less attract area within
industri capit alloc busi mix factor
contribut wide moat agil compar
narrow moat acquisit compani
thermo fisher scientif gener lower
roic oper less attract busi mix
opinion agil also appear oper
sharehold give us confid
futur
align
valu moder overvalu agil
share recent trade premium per share
fair valu estim roughli time project earn
water share recent trade premium
per share fair valu estim roughli time
project earn assum grow adjust
earn per share compound annual
next five year howev agil organ growth
prospect primarili margin expans water
need reli share repurchas half
annual bottom-lin growth
trim fair valu estim per share
base primarili larg share repurchas
activ expect near term like
done fair valu estim recent price hold
valuat impli price/adjust earn multipl
top line incorpor annual growth
next five year end market expect
growth led pharmaceut overal
growth expect double-digit biologic-rel growth
consid robust gener demand trend
new bioaccord lc-m product low-singl digit growth
small molecul could remain weak near
term given chines initi lower gener price
affect demand tool expect
low-single-digit growth annual basi
industri academic/govern market
power end market regul
pharmaceut end market also demand trend
intermedi term eventu may affect weaker
econom environ industri market well
budget constraint academ govern market
bottom line expect adjust earn per share
rise roughli compound annual next
five year sale growth primarili share
repurchas activ retreat slightli base
rel weak growth oper margin assum
remain roughli stagnant around
base-cas scenario also
manag goal increas net leverag roughli
time near term significantli boost
net interest expens go forward howev rise
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
estim assum greater-than-anticip uptak
firm new product innovation-rel mix benefit
quick rebound china scenario expect
sale growth compound annual
base-cas scenario oper margin
rise versu base-cas scenario
larg expect share repurchas think adjust
earn per share grow compound
annual next five year use base-cas
earn assumpt valu time project
earn bull-cas scenario
bear-cas scenario result fair valu
estim model incorpor roughli
annual top-lin growth oper margin fall
scenario assum increas price
pressur market share loss competit addit
potenti slowdown end market case net
incom actual declin slightli five year
forecast period adjust earn per share grow
compound annual scenario due expect share
repurchas activ near term use base-cas
earn assumpt valu time project
earn bear-cas scenario
instrument busi consist liquid chromatographi
mass spectrometri thermal analysi tool intellectu
properti on-going innov creat intang asset
moat sourc regulatori reproduc factor
contribut switch cost end user moat
sourc crucial advantag target
market advantag water enjoy
profit near top life scienc market
oper margin return invest capit excess
calcul
water offer differenti technolog protect
net interest expens off-set expect
share repurchas includ full billion share
repurchas author made earli end
modest repurchas outer year
forecast adjust earn per share basi
assum repurchas made made near
recent share price around per share outer
year repurchas made valuation-neutr level total
repurchas activ account roughli basi point
annual earn growth rate next
discount assumpt weight averag
cost capit around
give water medium uncertainti rate thank
sticki end market especi biopharmaceut
result rel steadi demand trend despit
variabl major end market -- industri
academic/govern
bull-cas scenario result per share fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
variou intang asset includ patent copyright
trademark water recent note patent portfolio
consist patent roughli
patent applic pend portfolio intellectu
properti innov prowess keep competitor
technolog sinc even slightli
differenti technic featur caus end user
prefer one tool anoth similar tool precis
differenti technolog signific moat sourc
differenti properti tool affect
perform accuraci speed variou project
enabl differenti product featur creat
intang asset inform decis use tool
specif applic particularli begin
project remain relev scientist earli project
phase must continu innov abil
innov contribut intang asset
busi well
gener
initi choic tool base intang
asset benefit substanti switch cost
end market importantli half water
develop
manufactur biopharmaceut sticki
busi contribut wide-moat statu
end market analyt tool critic compon
product method variou drug
specifi directli molecul regulatori approv
applic regul requir product method
throughout drug life cycl chang
manufactur process includ qualiti assur
qualiti control test typic perform tool
would requir approv regul regulatori
requir reproduc concern employe
train factor creat switch cost water
biopharmaceut custom result long
potenti benefit period water regul market
brand small molecul period last
year discoveri patent expir larg
molecul biolog period last even longer
difficult manufactur process also
use product method brand
manufactur reduc product variabl
adopt gener manufactur creat even
longer benefit period water specif molecul
overal concentr highli regul
biopharmaceut end market extend prospect
econom profit long period time
view wide-moat firm compar
favor mani narrow-moat life scienc
diagnost compani typic enjoy less concentr
regul field
see narrow still strong moat around water
other end market materi scienc food
environment applic due less-intens regulatori
pressur intang asset switch cost support
water moat end market well
throughout oper analyt instrument
long use live typic five year water
often benefit razor-and-blad busi model
life cycl half compani revenu
recur consum servic half
gener one-tim sale
instrument
informat price power organ appear
posit overal annual price appreci primarili
consum servic note
price power rise regul end market
correl well view wider moat
biopharmaceut applic compar end
market think relat interoper
column competit instrument therefor
less-regul market end user sensit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
technolog differ price relat product
servic end instrument life
cycl regul market howev think
reproducibility- training-rel switch cost
present water end market even
highli regul pharmaceut busi
water moat trend appear stabl us intang
asset front compani continu innov improv
perform analyt tool well user
interfac innov help maintain
market share initi project decis made
crucial on-going system placement
continu relev industri also much
water competit advantag associ regulatori
reproducibility-rel switch cost expect littl
chang firm moat exampl instrument
alreadi specifi manufactur process
biopharmaceut would unlik chang
water competitor benefit unless regulatori
requir biopharmaceut look like eas
substanti unlik opinion would
expect moat trend stay stabl given inher
sticki end market particular howev
manag appear open acquisit
past activ significantli alter water
exposur regul market tool requir
much flatter learn curv user view moat
moat trend could chang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
owat analyt instrument remain gold
standard sever applic especi lc-m
biopharmaceut firm regul preserv
consist recur sale mani year
owat remain extrem focus organ
creat potenti cash flow variabl
product fall favor end market face
ohistor maintain disciplin
capit alloc strategi preserv return
invest capit near top industri
expect continu even acquisit
owat continu benefit expand brand
gener biopharmaceut increas
food safeti environment test variou
ocompetit like agil thermo
fisher among other put consist pressur
water innov
owat increas debt leverag purchas
share fair valu estim may
best use sharehold capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end carri billion debt
billion cash invest net cash posit
howev compani aim net debt/ebitda
time tax reform given easi access cash
held oversea compani plan push signific cash
sharehold januari board
manag expect repurchas billion
author compani alreadi repurchas
million first quarter unless make
larg acquisit would expect complet
repurchas author reach new net leverag
goal time end expect water
gener billion free cash flow cumul
anticip compani
need issu debt complet author
still oper reason amount cash balanc
sheet water pay dividend made
larg acquisit recent year investor know
manag appetit acquisit appear
grown recent though would expect tuck-in
rather transform acquisit near
futur help maintain reason leverag
give water medium uncertainti rate thank
sticki end market especi biopharmaceut
result rel steadi demand trend despit
variabl major end market -- industri
academic/govern notabl though half
compani sale come system placement
delay even cancel challeng condit
exampl industri client may choos stretch
use exist system rather purchas new
pharmaceut develop project fail end market
econom downturn also
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
dynam chang seen chines
gener pharmaceut market earli system
purchas may fall even steadi pharmaceut end
market signific constraint govern research
budget could depress spend among academ
govern custom addit remain
technolog compani must innov remain
relev establish competitor new entrant
introduc better product develop stronger relationship
custom compani may lose market share well
abil extract price increas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
board
repres date owner name posit common share held report holder issuer
fidel manag research compani
new york mellon corp
share
fund
share
fund
maintain exemplari stewardship rate
asid keep innov prowess high level
water focu intern invest opportun
help maintain return invest capit well
peer gener
likelihood manag refrain larg
influenc
water
compani manag team appear align
sharehold although prefer direct use
return invest capit compens polici
manag team highlight roic high
prioriti think benefit sharehold
water continu avoid value-destroy capital-alloc
activ compens compani top manag
team also appear align sharehold
variabl compens structur heavili weight
incent base revenu adjust
recent chang manag financi strategi
creat uncertainti around stewardship go
forward though execut turnov
last year chri connel former
presid restor therapi group
replac dougla berthiaum ceo oconnel
also replac berthiaum chairman board
sherri buck becam cfo previou financi
execut experi libbey
new manag increas access cash
tax reform compani financi strategi chang
somewhat exampl compani increas
financi leverag repurchas share recogn
abl access debt market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
histor low interest rate question valuat
like pay share
remain fair valu estim also increas
net leverag net cash posit may make water
suscept downturn demand product
particularli one-tim instrument sale repres
half revenu chang add
uncertainti stewardship stori
otherwis strong histor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
agil remain wide moat
take fresh look top-tier analyt instrument
provid agil maintain wide
moat rate make uniqu life scienc
diagnost industri comparison cover
compani industri earn narrow moat rate
think agil heavi concentr
sticki end market -- biopharmaceut chemic
energi --
reproduc regulatori factor associ
tool contribut wider moat peer
firm enjoy exemplari stewardship rate well
specif disciplin acquisit record recent
year contribut return invest capit
doubl capit cost set apart industri
also help avoid less attract area within
industri capit alloc busi mix factor
contribut wide moat agil compar
narrow moat acquisit compani
thermo fisher scientif gener lower
roic oper less attract busi mix
opinion agil also appear oper
sharehold give us confid
futur
align
valu moder overvalu agil
share recent trade premium per share
fair valu estim roughli time project earn
water share recent trade premium
per share fair valu estim roughli time
project earn assum grow adjust
earn per share compound annual
next five year howev agil organ growth
prospect primarili margin expans water
need reli share repurchas half
annual bottom-lin growth
place review transfer
coverag new analyst expect publish new fair
valu estim second quarter
water end strong note anticip
slight increas fve jan
year solid
perform view may modestli increas
fair valu estim adjust
assumpt revenu adjust earn per share
growth respect fourth quarter
slightli surpass expect even
account much billion share repurchas
manag outlook adjust ep
year exce initi estim thank part
greater oper leverag
post constant-curr growth
improv perform previou quarter
year thank favor condit america
asia meanwhil thermal analysi segment overcam
weak seen third quarter constant
final quarter year
manag said demand europ india remain
challeng think quarter perform
combin stabl underli market condit new
product launch sustain comfort mid-single-digit
growth manag note consist improv
high-resolut mass spec area
weak firm much earli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
encourag water constant-curr
revenu growth biopharma market
compani recent lag close peer view
plan slightli boost near-term outlook segment
follow quarter better-than-expect result
think new product launch lc-m bioaccord
announc week help support growth
biopharma segment critic
water market segment post fourth-quart
result mostli line expect industri
appli segment sale increas constant-curr
basi consist perform throughout
academ govern sale growth slow
manag attribut weak
biomed research dont envis dramat shift
growth expect segment especi
recent govern academ spend
expect sinc earlier year still consid
market possess low- mid-single-digit growth
potenti long term even brexit
govern shutdown overal slow growth
concern repres potenti near-term headwind
macroeconom sensit custom group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
